Search

Your search keyword '"Blue, Laura J"' showing total 19 results
Start Over Author "Blue, Laura J"
19 results on '"Blue, Laura J"'

10. Comorbidities and the decision to undergo or forego destination therapy left ventricular assist device implantation: An analysis from the Trial of a Shared Decision Support Intervention for Patients and their Caregivers Offered Destination Therapy for End-Stage Heart Failure (DECIDE-LVAD) study

Author

Warraich, Haider J., primary, Allen, Larry A., additional, Blue, Laura J., additional, Chaussee, Erin L., additional, Thompson, Jocelyn S., additional, McIlvennan, Colleen K., additional, Flint, Kelsey M., additional, Matlock, Daniel D., additional, and Patel, Chetan B., additional

Published
2019
Full Text
View/download PDF

11. Stroke risk following implantation of current generation centrifugal flow left ventricular assist devices.

Author

Chiang, Yuting P., Cox, Daniel, Schroder, Jacob N., Daneshmand, Mani A., Blue, Laura J., Patel, Chetan B., DeVore, Adam D., Bishawi, Muath, and Milano, Carmelo A.

Subjects
HEART assist devices, STROKE, UNIVARIATE analysis, PROPORTIONAL hazards models, COMPETING risks, SURGICAL complications, RETROSPECTIVE studies
Abstract

Background and Aim: Stroke remains a significant complication of left ventricular assist device (LVAD) therapy. We performed a single-center retrospective study evaluating patients undergoing first-time HeartWare HVAD (Medtronic Inc) or HeartMate 3 (Abbott Inc) implantation from September 2009-February 2018.Methods: Exclusion criteria were age <18 and preoperative ECMO. The primary endpoint was stroke-free survival. Stroke was defined as new neurological deficits persisting >24 hours with corresponding radiographic evidence. Risk factors evaluated included demographics, medical comorbidities, heart failure etiology, LVAD indication, INTERMACS profile, and device type. Univariate predictors (P < .15) and variables clinically suspected to raise stroke risk were entered in a multivariate hazard regression model, specified using backward selection of covariates and accounting for competing risks of transplant/LVAD exchange.Results: A total of 163 HVAD and 84 HM3 patients were analyzed. Median follow up (until death, censoring for transplant/LVAD removal, or end of follow up) was 1.2 years in HVAD patients and 1.4 years in HM3 patients. Stroke occurred in 24 HVAD patients (15 ischemic, 9 hemorrhagic) and 6 HM3 patients (4 ischemic, 2 hemorrhagic). One-year stroke-free survival was 76.8% for HVAD and 84.3% for HM3. Thirty-day mortality following stroke was 41.7% for HVAD and 66.7% for HM3; 54.2% of HVAD strokes were disabling compared to 83.3% of HM3 strokes. Age, LVAD indication, and device type were associated (P < .15) with stroke on univariate analysis. On multivariate analysis, the HVAD was associated with significantly higher stroke risk (hazard ratio, 2.57; 95% confidence interval, 1.02-6.44; P = .045).Conclusions: Different LVAD models appear to be associated with significantly different stroke risks. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results